Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet Oncology

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(13)70596-5PMID 24439931PMCID PMC3954701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor

  2013cited by this paper
• Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.

  2013cited by this paper
• Determination of Human Anticytokine Autoantibody Profiles Using a Particle-Based Approach

  2012cited by this paper
• Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.

  2012cited by this paper
• IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

  2012cited by this paper
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cited by this paper
• Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

  2012cited by this paper
• Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

  2011cited by this paper
• Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

  2011cited by this paper
• A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

  2010cited by this paper
• Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?

  2010cited by this paper
• Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).

  2010cited by this paper
• Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas

  2010cited by this paper
• Cixutumumab

  2009cited by this paper
• The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

  2009cited by this paper
• Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.

  2009cited by this paper
• Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.

  2008cited by this paper
• Treatment of Advanced Thymoma and Thymic Carcinoma

  2008cited by this paper
• A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma

  2008cited by this paper
• Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion.

  2008cited by this paper
• Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

  2007cited by this paper
• Paraneoplastic diseases associated with thymoma

  2007cited by this paper
• A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma.

  2006cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.

  2004cited by this paper
• Thymic tumors.

  2004cited by this paper
• Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors.

  2003cited by this paper
• Anti‐cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon‐alpha, interferon‐omega and interleukin‐12 in patients with thymoma and/or myasthenia gravis

  2003cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables

  1983cited by this paper

• Neuro‐Cancer Interactions Shape Glioma Intratumoral Heterogeneity

  2025cites this paper
• Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review

  2025cites this paper
• Thymic malignancies: role of immunotherapy and novel approaches

  2024cites this paper
• Prognostic and immunological significance of metastasis-associated protein 3 in patients with thymic epithelial tumors

  2024cites this paper
• Narrative review of indication and management of induction therapy for thymic epithelial tumors

  2024cites this paper
• What Have We Learned from Molecularly Informed Clinical Trials on Thymomas and Thymic Carcinomas—Current Status and Future Directions?

  2024cites this paper
• Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review

  2024influential citation
• Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy.

  2024cites this paper
• Thymic epithelial tumor medical treatment: A narrative review.

  2024cites this paper
• Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies

  2024cites this paper
• Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures

  2023cites this paper
• Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review

  2023cites this paper
• Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis.

  2023cites this paper
• Obesity and endocrine-related cancer: The important role of IGF-1

  2023cites this paper
• Emerging therapies in thymic epithelial tumors (Review)

  2023cites this paper
• Real‐world study of treatment and outcome of type B2 + B3 thymoma: The neglected part of thymoma

  2023cites this paper
• Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

  2023cites this paper
• Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas

  2023cites this paper
• A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

  2022cites this paper
• Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword

  2022cites this paper
• Cixutumumab reveals a critical role for IGF-1 in adipose and hepatic tissue remodelling during the development of diet-induced obesity

  2022cites this paper
• Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study

  2022cites this paper
• Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours: A Systematic Review.

  2022cites this paper
• Detection of Neutralizing Anti‐Type 1 Interferon Autoantibodies

  2022cites this paper
• Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial

  2022cites this paper
• Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy

  2021cites this paper
• Systemic treatments for thymic tumors: a narrative review

  2021influential citation
• Bioinformatics analysis of the key potential ceRNA biomarkers in human thymic epithelial tumors

  2021cites this paper
• Mutational landscape of thymic epithelial tumors in a Chinese population: insights into potential clinical implications.

  2021cites this paper
• Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

  2021cites this paper
• Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

  2021cites this paper
• Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC

  2021cites this paper
• An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances

  2021influential citation
• Thymic stroma and TFII-I: towards new targeted therapies.

  2021cites this paper
• 复发性胸腺瘤的治疗

  2020cites this paper
• Thymic Malignancy-Updates in Staging and Management.

  2020cites this paper
• Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma

  2020cites this paper
• Insulin-Like Growth Factors Are Key Regulators of T Helper 17 Regulatory T Cell Balance in Autoimmunity.

  2020cites this paper
• The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives

  2020cites this paper
• Thymic epithelial tumors: From biology to treatment.

  2020cites this paper
• WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity

  2019cites this paper
• Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

  2019cites this paper
• Thymoma and Thymic Carcinoma

  2019cites this paper
• Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?

  2019cites this paper
• The role of targeted therapy in thymic carcinoma

  2019cites this paper
• A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

  2019cites this paper
• WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies

  2019cites this paper
• Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas

  2019cites this paper
• Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy

  2019cites this paper
• High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors.

  2019cites this paper
• Deciphering the biology of thymic epithelial tumors

  2019cites this paper
• IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness.

  2018cites this paper
• Thymic Tumors: Revisiting Autoimmunity to Give a Chance to Immunotherapy.

  2018cites this paper
• A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma

  2018influential citation
• Metastatic Thymic Carcinoma with Long Survival After Treatment with Sunitinib

  2018cites this paper
• What Can We Learn From the French Experience in Systemic Treatment of Thymic Epithelial Tumors?

  2018cites this paper
• Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

  2018cites this paper
• Systemic treatments for thymoma and thymic carcinoma: A systematic review.

  2018cites this paper
• Targeted therapies for the treatment of patients with advanced, recurrent or relapsed thymic epithelial tumours

  2018cites this paper
• Relationship between thymic epithelial tumors and autoimmune disorders

  2018cites this paper
• Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas

  2018cites this paper
• Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity

  2017cites this paper
• Novel Agents in the Treatment of Thymic Malignancies

  2017cites this paper
• Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer.

  2017cites this paper
• Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis

  2017cites this paper
• Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

  2017cites this paper
• CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies.

  2017cites this paper
• Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

  2017cites this paper
• Thymomas and Thymic Tumors

  2017cites this paper
• Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells

  2017cites this paper
• PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

  2016cites this paper
• Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.

  2016cites this paper
• Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC

  2016cites this paper
• Induction Therapy for Thymoma.

  2016cites this paper
• Thymic malignancies: Moving forward with new systemic treatments.

  2016cites this paper
• Rare frequency of gene variation and survival analysis in thymic epithelial tumors

  2016cites this paper
• The clinical features, diagnosis and management of recurrent thymoma

  2016cites this paper
• The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

  2016cites this paper
• Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor.

  2016cites this paper
• Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations

  2016cites this paper
• Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.

  2016cites this paper
• Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?

  2016cites this paper
• Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

  2016influential citation
• A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

  2016cites this paper
• Systemic Therapies in Thymic Malignancies

  2016cites this paper
• Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

  2016cites this paper
• Diagnose und Therapie des Thymuskarzinoms

  2016cites this paper
• rare frequency of gene variation and survival analysis in thymic epithelial tumors

  2016cites this paper
• rare frequency of gene variation and survival analysis in thymic epithelial tumors

  2016cites this paper
• Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma

  2015cites this paper
• Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.

  2015cites this paper
• New findings on thymic epithelial tumors: Something is changing.

  2015cites this paper
• Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor

  2015cites this paper
• The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link

  2015cites this paper
• Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.

  2015cites this paper
• Chemotherapy and prognosis in advanced thymic carcinoma patients

  2015cites this paper
• The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

  2015cites this paper
• Multiorgan autoimmune manifestations associated with thymoma.

  2015cites this paper
• Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma.

  2015cites this paper
• Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

  2015cites this paper